balance equationreview2016-12-31
Difference 7924000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.
Revenue
$66.80M
Fiscal year ended 2025-12-31Operating income
$6.31M
Fiscal year ended 2025-12-31Free cash flow
Unavailable
Fiscal year ended 2025-12-31Valuation, from the filing
| Public float | $160.30M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $2.77 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 18.7× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 2.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 2.7× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| Net margin | 12.8% | 86th | |
| Operating margin | 9.5% | 84th | |
| SBC / revenue | 6.5% | 25th | |
| Current ratio | 7.59x | 72th | |
| Revenue YoY growth | 39.2% | 72th | |
| Effective tax rate | 3.0% | 31th | |
| R&D / revenue | 57.6% | 37th |
Spero Therapeutics, Inc. (SPRO) reported revenue of $66.80M and net income of $8.57M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Spero Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.80M | $47.98M | $103.78M | $53.51M | $18.26M | $9.33M | $18.15M | $3.97M | $1.98M | $335.00K |
| Cost of revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating income | $6.31M | -$73.36M | $21.48M | -$42.20M | -$87.97M | -$79.11M | -$63.22M | -$42.81M | -$41.73M | -$33.22M |
| Net income | $8.57M | -$68.57M | $22.81M | Unavailable | -$89.80M | -$78.30M | -$60.90M | -$41.70M | -$38.74M | -$25.49M |
| Research & development | $38.47M | $96.76M | $51.44M | $47.59M | $64.53M | $67.00M | $65.78M | $33.88M | $32.87M | $26.33M |
| Weighted-average diluted shares | shares 59.04M | shares 54.04M | shares 52.99M | shares 37.59M | shares 30.90M | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Pretax income | $8.83M | -$68.57M | $25.40M | -$46.42M | -$89.76M | -$78.28M | -$60.92M | -$41.66M | -$39.89M | -$32.64M |
| Income tax expense | $261.00K | $0 | $2.60M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Diluted EPS | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $21.18M | $23.70M | $25.55M | $36.48M | $41.70M | $21.44M | $15.59M | $12.89M | $10.84M | $7.22M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $40.26M | $52.89M | $76.33M | $109.11M | $112.58M | $85.21M | $29.73M | $34.08M | $87.29M | $10.32M |
| Total assets | $68.92M | $110.54M | $182.39M | $124.80M | $171.07M | $153.45M | $106.10M | $129.01M | $93.48M | $13.77M |
| Current assets | $67.29M | $107.28M | $131.21M | $113.57M | $157.87M | $139.14M | $95.41M | $124.22M | $92.06M | $11.87M |
| Total liabilities | $9.90M | $64.42M | $75.50M | $48.87M | $82.78M | $21.41M | $31.53M | $13.15M | $8.52M | $7.41M |
| Current liabilities | $8.87M | $49.07M | $37.15M | $21.65M | $18.67M | $14.34M | $26.66M | $12.32M | $8.16M | $6.92M |
| Total equity incl. NCI | $59.02M | $46.12M | $106.89M | $75.93M | $88.29M | $132.04M | $74.57M | $115.86M | $84.96M | -$49.25M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $47.68M |
| Inventory | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts receivable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $693.00K | $7.31M | $1.38M | $617.00K | $1.10M | $1.16M | $4.15M | $3.60M | $3.47M | $1.14M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.62M | -$23.44M | -$33.00M | -$7.73M | -$64.35M | -$85.87M | -$50.02M | -$39.62M | -$39.11M | -$28.96M |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $157.00K | $314.00K | $2.44M | $27.00K | $830.00K |
| Investing cash flow | Unavailable | Unavailable | $0 | $33.81M | $7.67M | $10.47M | $29.53M | -$83.16M | -$27.00K | -$830.00K |
| Financing cash flow | Unavailable | $0 | $221.00K | -$29.55M | $84.05M | $130.88M | $16.14M | $69.52M | $116.11M | $34.41M |
| Net change in cash | -$12.62M | -$23.44M | -$32.77M | -$3.48M | $27.38M | $55.48M | -$4.35M | -$53.26M | $76.97M | $4.62M |
| Stock-based compensation | $4.32M | $7.79M | $7.93M | $9.12M | $9.43M | $4.89M | $3.78M | $2.75M | $1.43M | $180.00K |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $0 | $2.00K | $367.00K | $869.00K | $646.00K | $761.00K | $750.00K | $409.00K | $363.00K | $279.00K |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | -$50.33M | -$42.06M | -$39.14M | -$29.79M |
| Gross margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | 9.5% | -152.9% | 20.7% | -78.9% | -481.9% | -847.9% | -348.4% | -1079.3% | -2108.6% | -9916.7% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | -277.4% | -1060.5% | -1977.7% | -8892.2% |
| SBC / revenue | 6.5% | 16.2% | 7.6% | 17.0% | 51.7% | 52.4% | 20.8% | 69.3% | 72.1% | 53.7% |
| Current ratio | 7.59x | 2.19x | 3.53x | 5.25x | 8.46x | 9.70x | 3.58x | 10.08x | 11.29x | 1.72x |
| Revenue YoY growth | 39.2% | -53.8% | 94.0% | 193.1% | 95.7% | -48.6% | 357.6% | 100.4% | 490.7% | Unavailable |
| Net margin | 12.8% | -142.9% | 22.0% | Unavailable | Unavailable | -839.2% | -335.6% | -1051.4% | -1957.7% | -7609.3% |
| R&D / revenue | 57.6% | 201.7% | 49.6% | 88.9% | 353.5% | 718.1% | 362.5% | 854.4% | 1660.9% | 7860.6% |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 1.7% | 61.4% | 1.4% | 247.8% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 3.0% | Unavailable | 10.2% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SPRO in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.